Caribou Biosciences (CRBU) Equity Ratio (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Equity Ratio data on file, last reported at 0.68 in Q1 2026.

• Quarterly Equity Ratio fell 13.74% year-over-year to 0.68 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.68 (down 13.74% YoY) and the FY2025 annual result came in at 0.7, down 13.71% from the prior year.
• Equity Ratio declined to 0.68 in Q1 2026 per CRBU's latest filing, from 0.7 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.87 in Q3 2023 and bottomed at 0.68 in Q1 2026.
• The 5-year median for Equity Ratio is 0.81 (2024), against an average of 0.8.
• The widest annual swing landed in 2022, when Equity Ratio jumped 374.21%; it then decreased 13.74% in 2026.
• Tracing CRBU's Equity Ratio over 5 years: stood at 0.8 in 2022, then advanced by 5.89% to 0.85 in 2023, then retreated by 5.28% to 0.81 in 2024, then fell by 13.71% to 0.7 in 2025, then slipped by 1.72% to 0.68 in 2026.
• Per Business Quant, the three latest CRBU Equity Ratio figures stand at 0.68 (Q1 2026), 0.7 (Q4 2025), and 0.73 (Q3 2025).

Peer Comparison